References
- Babbs C.F., Dewitt D.P., Vorhees W.D., McCaw J.S., Chan R.C. Theoretical feasibility of vasodilator enhanced local tumour heating. European Journal of Cancer and Clinical Oncology 1982; 18: 1137–1146
- Bhujwalla Z.M., Tozer G.M., Field S.B., Maxwell R.J., Griffiths J.R. The Response of RIF-1 tumours to the vasodilator hydralazine, assessed by 31P-MRS, and measurements of blood flow and blood pressure. Radiotherapy and Oncology 1990; 19: 281–291
- Brown J.M. Exploitation of bioreductive agents with vasoactive drugs. Proceedings of the 8th International Congress on Radiation Research, EdinburghU.K. Taylor & Francis, London 1987; 2: 719–724
- Chaplin D.J., Acker B. Potentiation of RSU-1069 tumour cytoxicity by hydralazine: a new approach to selective therapy. International Journal of Radiation Oncology, Biology and Physics 1987; 13: 579–586
- Denekamp J. Residual damage in mouse skin 5 to 8 months after irradiation. Radiology 1975; 115: 191–195
- Falk P. The vascular pattern of the spontaneous C3H mouse mammary carcinoma and its significance in radiation response and in hyperthermia. European Journal of Cancer and Clinical Oncology 1980; 16: 203–217
- Falk P. Differences in vascular pattern between the spontaneous and the transplanted C3H mouse mammary carcinoma. European Journal of Cancer and Clinical Oncology 1982; 18: 155–165
- Hill S.A., Smith K.A., Denekamp J. Reduced thermal sensitivity of the vasculature in a slowly growing tumour. International Journal of Hyperthermia 1989; 5: 359–370
- Horsmann M.R., Christensen K.L., Overgaard J. Hydralazine induced enhancement of hyperthermic damage in a C3H mammary carcinoma in vivo. International Journal of Hyperthermia 1989; 5: 123–136
- Jain R.K. Determinants of tumour blood flow: a review. Cancer Research 1988; 48: 2641–2658
- McCredie J.A., Inch W.R., Sutherland E.M. Differences in growth and morphology between the spontaneous C3H mammary carcinoma in the mouse and its syngeneic transplants. Cancer 1971; 7: 635–642
- Okunieff P., Kallinowski K., Vaupel P., Neuringer L. Effect of hydralazine-induced vasodilatation on the energy metabolism of murine tumours studied by in vivo31P-nuclear magnetic resonance spectroscopy. Journal of the National Cancer Institute 1988; 80: 745–750
- Stratford I.J., Godden J., Howells N., Embling P., Adams G.E. Manipulation of tumour oxygenation by hydralazine increases the potency of bioreductive radiosensitizers and enhances the effect of melphalan in experimental tumours. Proceedings of the 8th International Congress on Radiation Research, EdinburghU.K. Taylor & Francis, London 1987; 2: 737–742
- Stratford I.J., Adams G.E., Godden J., Howells N. Induction of tumour hypoxia post irradiation; a method of increasing the sensitizing efficiency of misondiazole and RSU-1069 in vivo. International Journal of Radiation Biology 1989; 55: 411–422
- Tozer G.M., Bhujwalla Z.M., Griffiths J.R., Maxwell R.J. Phosphorous-31 magnetic resonance spectroscopy and blood perfusion of the RIF-1 tumour following X-irradiation. International Journal of Radiation Oncology, Biology and Physics 1989; 16: 155–164
- Tozer G.M., Maxwell R.J., Griffiths J.R., Pham F. Modification of 31P magnetic resonance spectra of a rat tumour using vasodilators and its relation to hypotension. British Journal of Cancer 1990; 62: 553–560
- Williams J.P., Coggle J.E., Charles M.W., Wells J. Skin carcinogenesis in the mouse following uniform and non-uniform β-irradiation. British Journal of Radiology 1986, Suppl. 19: 61–64